## **ADEOS - Adherence evaluation of osteoporosis treatment**

Head :Leclerc-Zwirn Christel, Laboratoire GSK

## Last update : 01/01/2018 | Version : 1 | ID : 151

General	
Identification	
Detailed name	Adherence evaluation of osteoporosis treatment
Sign or acronym	ADEOS
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	CNIL : 770334
General Aspects	
Medical area	Rheumatology
Others (details)	Osteoporosis
Keywords	adhesion, tool, osteoporosis, observance, persistence
Scientific investigator(s) (Contact)	
Name of the director	Leclerc-Zwirn
Surname	Christel
Phone	+33 (0)1 39 17 86 96
Email	christel.c.leclerc-zwirn@gsk.com
Unit	Laboratoire GSK
Collaborations	
Funding	
Funding status	Private
-	
Details	GSK laboratory

Sponsor(s) or organisation(s) responsible	Laboratoire GSK
Organisation status	Private
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is carried out by an intermediary	A selection of health care professionals
Database recruitment is is made on the basis of:	Medication(s) taken
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	The source population (potentially eligible patients) is represented by the patients wherein a treatment for osteoporosis from among those defined in the inclusion criteria is prescribed during a spontaneous consultation of a general practitioner who has accepted to participate in the study. Participating doctors will systematically and consecutively include up to 3 patients who meet all of the eligibility criteria.
Database objective	
Main objective	Finalize and validate a self-administered instrument developed to evaluate adhesion to the treatment of postmenopausal osteoporosis
Inclusion criteria	Woman; Over the age of 50 years; Patient to whom has been prescribed one of the following osteoporosis treatments in the six months prior to the inclusion starting date: bisphosphonates, selective estrogen receptor modulators (SERM), or strontium ranelate; Patient fluent in French and who has the cognitive and functional ability required to complete the self-questionnaires included in the study on their own;

Informed patient who has given their oral consent to participate in this study

Population type	
Age	Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
Population covered	Sick population
Gender	Woman
Geography area	National
Detail of the geography area	France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2008
Date of last collection (YYYY or MM/YYYY)	2008
Size of the database	
Size of the database (number of individuals)	< 500 individuals
Details of the number of individuals	350
Data	
Database activity	Data collection completed
Type of data collected	Clinical data Declarative data
Clinical data (detail)	Direct physical measures Medical registration
Declarative data (detail)	Paper self-questionnaire
Presence of a biobank	No
Health parameters studied	Others
Other (detail)	adherence, compliance, persistence

Data collection method	Two types of data will be collected during the study. Data concerning the subjective considerations of the patients will be collected via self-questionnaires. Medical data will be collected through computerized medical collection (""questions on the screen"") completed by the doctor.
Participant monitoring	No
Links to administrative sources	No
Promotion and access	
Promotion	
Promotion Access	
	Publications: Breuil et al. Osteoporosis International. 2011
Access Terms of data access (charter for data provision, format of	